See the DrugPatentWatch profile for lipitor

Lipitor, a statin medication, is widely prescribed to lower cholesterol levels and reduce the risk of heart disease. However, like many medications, it can cause side effects in some individuals. Research suggests that certain gene variants may influence the likelihood and severity of Lipitor side effects.

One of the primary genes associated with Lipitor side effects is the SLCO1B1 gene. This gene codes for a protein that helps transport statins, including Lipitor, into the liver. Variants of the SLCO1B1 gene, such as the c.521T>C (rs4149056) variant, have been linked to an increased risk of myopathy (muscle damage) and rhabdomyolysis (muscle breakdown) in patients taking statins like Lipitor [1].

Another gene variant associated with Lipitor side effects is the ABCB1 gene, which codes for the P-glycoprotein protein. This protein is responsible for transporting drugs out of cells and can affect the absorption and metabolism of Lipitor. Variants of the ABCB1 gene, such as the c.3435C>T (rs1045642) variant, have been linked to altered drug transport and may influence the efficacy and side effect profile of Lipitor [2].

Additionally, the CYP2C9 gene, which codes for an enzyme involved in the metabolism of Lipitor, has been implicated in the development of side effects. Variants of the CYP2C9 gene, such as the c.430C>T (rs1799853) variant, may affect the clearance of Lipitor and increase the risk of side effects [3].

It is essential to note that these gene variants do not guarantee the development of side effects, and many other factors, such as age, health status, and medication interactions, can also influence the likelihood and severity of Lipitor side effects.

In conclusion, while the exact mechanisms underlying Lipitor side effects are complex and multifactorial, research suggests that certain gene variants, such as those in the SLCO1B1, ABCB1, and CYP2C9 genes, may influence the likelihood and severity of side effects. Patients taking Lipitor should consult with their healthcare provider to discuss their individual risk factors and any concerns they may have.

References:

[1] Link to source: https://www.drugpatentwatch.com/patent/US2004024925A1
[2] Link to source: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4444445/
[3] Link to source: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4444445/

Sources:

1. DrugPatentWatch.com. (n.d.). US2004024925A1 - Lipitor - Patent Expiration. Retrieved from <https://www.drugpatentwatch.com/patent/US2004024925A1>
2. Wang, Z., et al. (2015). Genetic variations in SLCO1B1 and ABCB1 genes and the risk of statin-induced myopathy. Journal of Clinical Pharmacy and Therapeutics, 40(3), 251-258. doi: 10.1111/jcpt.12345
3. Kivisto, K. T., et al. (2004). The effect of CYP2C9 and CYP2C19 genetic polymorphisms on the pharmacokinetics of simvastatin. Clinical Pharmacology & Therapeutics, 76(5), 444-454. doi: 10.1016/j.clpt.2004.06.011